Listen to "Reality Check with Ben Swann" on Spreaker.

Goldman Sachs Questions Whether Curing Disease is Economically Sustainable

Must Read

Interview on The Last American Vagabond: Fighting Modern Censorship

In this interview for The Last American Vagabond, I had a fantastic discussion with founder Ryan Cristian about how...

NEW Study Shows HYDR0XYCHL0R0QUINE Cuts COVID Death Rate In Half

It is the most controversial word on social media HYDR0XYCHL0R0QUlNE. What is the truth about this drug? It turns...

“Masks Make Us Slaves” Massive Protests in Germany Over C0VlD Lockdown

Massive protests in Berlin, Germany over the weekend as reports of 10's of thousands up to possibly a million...
Jay Syrmopoulos
Jay Syrmopoulos is a geopolitical analyst, freethinker, and ardent opponent of authoritarianism. He is currently a graduate student at the University of Denver pursuing a masters in Global Affairs and holds a BA in International Relations. Jay's writing has been featured on both mainstream and independent media - and has been viewed tens of millions of times.

New York, NY— Goldman Sachs, in an April report to clients, addressed an ethical conundrum facing pharmaceutical and biotechnology companies in regard to futuristic cures based on cutting edge gene therapy: “one shot cures,” rather than the model of continuous treatment, could be difficult for some “medicine developers looking for a sustained cash flow.”

In a report entitled “The Genome Revolution” Goldman Sachs analyst Salveen Richter asked, “Is curing patients a sustainable business model?”

“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients on April 10. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”

- Newsletter -

Richter highlighted the case of Gilead Sciences’ treatments for hepatitis C, which reportedly achieved cure rates of over 90 percent, as a cautionary tale.

“GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients,” the Goldman Sachs analyst wrote. “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise.”

CNBC reported that in 2015 the company’s U.S. sales for hepatitis C treatments peaked at $12.5 billion but have fallen each following year. Goldman has estimated that U.S. sales of these treatments in 2018 will be under $4 billion, according to the report.

The report proposed three possible solutions for biotech companies:

“Solution 1: Address large markets: Hemophilia is a $9-10bn WW market (hemophilia A, B), growing at ~6-7% annually.”

“Solution 2: Address disorders with high incidence: Spinal muscular atrophy (SMA) affects the cells (neurons) in the spinal cord, impacting the ability to walk, eat, or breathe.”

“Solution 3: Constant innovation and portfolio expansion: There are hundreds of inherited retinal diseases (genetics forms of blindness) … Pace of innovation will also play a role as future programs can offset the declining revenue trajectory of prior assets.”

The issues addressed in the report essentially means that mega-profits will be reduced to extremely large profits— but for more rare diseases, however, there is a concern that due to reduced potential income there may not be enough profits for biotech firms to justify the cost of research and clinical trials, usually at the cost of at least $1 billion.

- Advertisement -

Featrued Sponsors

Unstoppable Domains

Uncensorable blockchain domains. Every domain purchase supports Ben Swann and Truth in Media

Holland Center

Holland Center is a day treatment program and medical clinic for children with autism.

Pure VPN

Military grade privacy on all devices.
- Advertisement -

Latest News

video

Interview on The Last American Vagabond: Fighting Modern Censorship

In this interview for The Last American Vagabond, I had a fantastic discussion with founder Ryan Cristian about how...
video

NEW Study Shows HYDR0XYCHL0R0QUINE Cuts COVID Death Rate In Half

It is the most controversial word on social media HYDR0XYCHL0R0QUlNE. What is the truth about this drug? It turns out there was a study...
video

“Masks Make Us Slaves” Massive Protests in Germany Over C0VlD Lockdown

Massive protests in Berlin, Germany over the weekend as reports of 10's of thousands up to possibly a million or more people took to...
video

Investigation: C0VlD Positive Results for People Who Were Never Given Tests?

Hundreds of people across the United States have been complaining that they are receiving calls from clinics and medical offices claiming that they have...
video

New CDC and WHO Study Proves “No Evidence” Face Masks Prevent Virus

FB's so called “fact checkers” have struck again, claiming that my report on the science that proves that wearing face masks, especially in non-medical...
- Advertisement -

More Articles Like This